Search Results

Displaying Results 176-200 of 435 "'HT'"

Dec 02, 2025, 08:00 ET Leidos explosive trace detection system achieves latest EU security standard

B220-HT explosive trace detection (ETD) system has achieved G1 Standard certification ahead of the European Civil Aviation Conference's (ECAC) latest regulatory

More news about: Leidos


Dec 02, 2025, 02:27 ET Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting

KCNT1, SCN2A).About BexicaserinBexicaserin (LP352) is an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist with no engagement of the 5-HT2B and 5-HT2A receptor subtypes, potentially minimizing the risk of cardiovascular toxicity.11 The most common TEAEs

More news about: H. Lundbeck A/S


Dec 02, 2025, 02:25 ET Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting

KCNT1, SCN2A).About BexicaserinBexicaserin (LP352) is an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist with no engagement of the 5-HT2B and 5-HT2A receptor subtypes, potentially minimizing the risk of cardiovascular toxicity.11 The most common TEAEs

More news about: H. Lundbeck A/S


Nov 25, 2025, 03:39 ET Mumbai Climate Week Welcomes NSE as Innovation Challenge Partner to Drive India's Next Wave of Climate Innovation

solution platforms on the global stage.Government of Maharashtra, Majhi Vasundhara, Brihanmumbai Municipal Corporation (BMC),Monitor Deloitte, HT Parekh Foundation, India Climate Collaborative (ICC), Shakti Foundation, WRI India UNICEF, Rainmatter Foundation, Mahindra Group, Climate Group, NGMA

More news about: Project Mumbai


Nov 21, 2025, 02:03 ET INTAMSYS lanza FUNMAT PRO 310 APOLLO

mantenido a la vanguardia de esta transformación industrial.En 2016, INTAMSYS lanzó su primera impresora de alta temperatura, la FUNMAT HT, convirtiéndose en una de las primeras empresas en lograr una impresión FFF estable de PEEK. En una época en la que imprimir bien con PLA era

More news about: INTAMSYS


Nov 21, 2025, 02:02 ET INTAMSYS stellt den FUNMAT PRO 310 APOLLO vor: Kontinuierliche Produktion neu definiert mit hochgeschwindigkeitsfähigem, hochfestem PAEK-3D-Druck

industriellen Wandel stets eine Vorreiterrolle gespielt.Im Jahr 2016 brachte INTAMSYS seinen ersten Hochtemperaturdrucker auf den Markt, den FUNMAT HT. Damit war es eines der ersten Unternehmen, das stabilen FFF-Druck von PEEK erreichte. Als „PLA gut drucken können" noch der Maßstab war, hat

More news about: INTAMSYS


Nov 21, 2025, 01:56 ET INTAMSYS lance l'imprimante FUNMAT PRO 310 APOLLO : une redéfinition de la production en continu grâce à l'impression en 3D PAEK à haute vitesse et à haute résistance

été à l'avant-garde de cette transformation industrielle.En 2016, INTAMSYS a sorti sa première imprimante à haute température, la FUNMAT HT. C'était alors l'une des premières entreprises à proposer une impression FFF stable du PEEK. À une époque où l'impression PLA de qualité était

More news about: INTAMSYS


Nov 21, 2025, 00:40 ET INTAMSYS lanceert de FUNMAT PRO 310 APOLLO: Het herdefiniëren van continue productie met hoge snelheid, hoge-sterkte PAEK 3D-printen

heeft altijd voorop gelopen bij deze industriële transformatie.In 2016 lanceerde INTAMSYS zijn eerste hogetemperatuurprinter, de FUNMAT HT, waarmee het een van de eerste bedrijven was die stabiel FFF-printen van PEEK kon realiseren. In een tijd waarin "goed PLA printen" nog steeds

More news about: INTAMSYS


Nov 21, 2025, 00:38 ET INTAMSYS lancia FUNMAT PRO 310 APOLLO: ridefinire la produzione continua con la stampa 3D del PAEK ad alta velocità e resistenza

in prima linea in questa trasformazione industriale.Nel 2016 INTAMSYS ha lanciato la sua prima stampante ad alta temperatura, la FUNMAT HT, diventando una delle prime aziende a ottenere la FFF stabile di PEEK. In un'epoca in cui la "stampa di alta qualità del PLA" era ancora un punto

More news about: INTAMSYS


Nov 20, 2025, 08:13 ET Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities

Technical expertise, SDKs, and APIs that can support algorithmic modeling across Hoth's programs, including HT-001 (pruritus reduction), HT-KIT (mast-cell modulation), HT-ALZ (GDNF-based Alzheimer's therapy), and its metabolic-disease initiatives developed in partnership with leading academic

More news about: Hoth Therapeutics, Inc.


Nov 18, 2025, 08:30 ET Biomarker Testing: Pushing the Limits of Ultrasensitivity, Upcoming Webinar Hosted by Xtalks

like neuroscience, where analytes are often present at very low concentrations in peripheral circulation. Attendees will gain insight into NULISA™/Argo™ HT capabilities and how the platform pushes the limits of biomarker sensitivity and applies to challenging biomarker-detection scenarios. The featured speakers

More news about: Xtalks


Nov 18, 2025, 04:01 ET INTAMSYS Launches the FUNMAT PRO 310 APOLLO: Redefining Continuous Production with High-Speed, High-Strength PAEK 3D Printing

the forefront of this industrial transformation. In 2016, INTAMSYS launched its first high-temperature printer, the FUNMAT HT, becoming one of the earliest companies to achieve stable FFF printing of PEEK. At a time when "printing PLA well" was still a benchmark, INTAMSYS

More news about: INTAMSYS


Nov 18, 2025, 03:15 ET INTAMSYS Launches the FUNMAT PRO 310 APOLLO: Redefining Continuous Production with High-Speed, High-Strength PAEK 3D Printing

the forefront of this industrial transformation. In 2016, INTAMSYS launched its first high-temperature printer, the FUNMAT HT, becoming one of the earliest companies to achieve stable FFF printing of PEEK. At a time when "printing PLA well" was still a benchmark, INTAMSYS

More news about: INTAMSYS


Nov 14, 2025, 09:26 ET Curis to Present at Upcoming 30th Annual SNO Meeting

November 21, 2025 – 4:30 PM ET (11:30 AM HT)

More news about: Curis, Inc.


Nov 12, 2025, 15:46 ET Garantir la fiabilité dans le cadre de la transition énergétique : KEMA Labs soutient des projets HT critiques dans toute l'Europe

matière de durabilité. Alors que les services publics s'efforcent de respecter les délais serrés des projets, la fiabilité des composants haute tension (HT) devient primordiale. KEMA Labs est en première ligne pour assurer cette fiabilité grâce à des tests de mise en service rigoureux qui permettent

More news about: KEMA Labs, a CESI Business Unit


Nov 11, 2025, 13:53 ET Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti® and Rexulti® driven by additional investments

to adhere to local requirements in some countries. 5 Acts as a partial agonist at 5-HT1A and dopamine D2 receptors at similar potency, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors. 6 Complete Response Letter Received 20 September

More news about: H. Lundbeck A/S


Nov 11, 2025, 13:38 ET Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti® and Rexulti® driven by additional investments

to adhere to local requirements in some countries. 5 Acts as a partial agonist at 5-HT1A and dopamine D2 receptors at similar potency, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors. 6 Complete Response Letter Received 20 September

More news about: H. Lundbeck A/S


Nov 11, 2025, 08:48 ET LifeKnight, Inc. Appoints Security Industry Leader Buffy Payne as Chief Security Officer

Payne is a respected member of professional security associations including InfraGard, DSAC, OSAC, IAFCI, and HT-CIA, and is widely recognized for her advocacy of veterans, first responders, and women in security. Through her involvement with FEW-Atlanta and

More news about: LifeKnight, Inc.


Nov 10, 2025, 08:15 ET Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting

Ofirnoflast (HT-6184) Reduces Oxidized Mitochondrial DNA in Patients with Low-Risk Myelodysplastic SyndromeSaturday, December 6, 2025; 5:30 P.M. – 7:30 P.M. EST The Novel Allosteric NEK7 Inhibitor Ofirnoflast (HT-6184) Demonstrates

More news about: Halia Therapeutics


Nov 10, 2025, 08:15 ET Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting

Ofirnoflast (HT-6184) Reduces Oxidized Mitochondrial DNA in Patients with Low-Risk Myelodysplastic SyndromeSaturday, December 6, 2025; 5:30 P.M. – 7:30 P.M. EST The Novel Allosteric NEK7 Inhibitor Ofirnoflast (HT-6184) Demonstrates

More news about: Halia Therapeutics


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.